Nkarta, Inc. (NKTX)
NASDAQ: NKTX · Real-Time Price · USD
2.500
+0.020 (0.81%)
At close: Nov 20, 2024, 4:00 PM
2.549
+0.049 (1.96%)
After-hours: Nov 20, 2024, 7:44 PM EST
Nkarta Employees
Nkarta had 150 employees as of December 31, 2023. The number of employees decreased by 13 or -7.98% compared to the previous year.
Employees
150
Change (1Y)
-13
Growth (1Y)
-7.98%
Revenue / Employee
n/a
Profits / Employee
-$737,393
Market Cap
176.42M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 150 | -13 | -7.98% |
Dec 31, 2022 | 163 | 27 | 19.85% |
Dec 31, 2021 | 136 | 41 | 43.16% |
Dec 31, 2020 | 95 | - | - |
Related Stocks
Company Name | Employees |
---|---|
Biodesix | 217 |
Caribou Biosciences | 158 |
Tenaya Therapeutics | 140 |
Heron Therapeutics | 126 |
Stereotaxis | 122 |
Inozyme Pharma | 59 |
DiaMedica Therapeutics | 19 |
Galectin Therapeutics | 14 |
NKTX News
- 9 days ago - Nkarta to Participate in an Upcoming Investor Conference - GlobeNewsWire
- 13 days ago - Nkarta Reports Third Quarter 2024 Financial Results and Corporate Highlights - GlobeNewsWire
- 6 weeks ago - Top 3 Health Care Stocks Which Could Rescue Your Portfolio This Month - Benzinga
- 2 months ago - Nkarta to Participate in Upcoming Investor Conference - GlobeNewsWire
- 3 months ago - Nkarta: NK Cell Therapy Biotech With Good Standing Targeting R/R NHL Patients - Seeking Alpha
- 3 months ago - Correction: Nkarta Reports Second Quarter 2024 Financial Results and Corporate Highlights - GlobeNewsWire
- 3 months ago - Nkarta Reports Second Quarter 2024 Financial Results and Corporate Highlights - GlobeNewsWire
- 4 months ago - Nkarta Announces Initiation of Investigator-Sponsored Clinical Trial Evaluating NKX019 for Systemic Lupus Erythematosus - GlobeNewsWire